A detailed history of Abn Amro Investment Solutions transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Abn Amro Investment Solutions holds 24,117 shares of BMY stock, worth $1.13 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
24,117
Previous 24,821 2.84%
Holding current value
$1.13 Million
Previous $1.15 Billion 5.33%
% of portfolio
0.02%
Previous 0.02%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 07, 2025

SELL
$43.31 - $48.98 $30,490 - $34,481
-704 Reduced 2.84%
24,117 $1.09 Billion
Q2 2025

Aug 08, 2025

BUY
$44.12 - $59.6 $1.1 Million - $1.48 Million
24,821 New
24,821 $1.15 Billion
Q4 2024

Sep 04, 2025

SELL
$51.92 - $59.94 $342,827 - $395,783
-6,603 Reduced 20.67%
25,338 $1.43 Billion
Q3 2024

Sep 04, 2025

BUY
$39.66 - $51.75 $282,379 - $368,460
7,120 Added 28.69%
31,941 $1.65 Billion
Q2 2024

Sep 04, 2025

BUY
$40.25 - $52.99 $163,495 - $215,245
4,062 Added 16.37%
28,883 $1.2 Billion
Q1 2024

Sep 05, 2025

SELL
$47.98 - $54.4 $13,242 - $15,014
-276 Reduced 1.87%
14,504 $787 Million
Q4 2023

Sep 05, 2025

BUY
$48.48 - $57.85 $38,638 - $46,106
797 Added 5.7%
14,780 $758 Million
Q3 2023

Nov 07, 2025

SELL
$57.89 - $64.73 $586,657 - $655,973
-10,134 Reduced 42.02%
13,983 $812 Million
Q3 2023

Nov 03, 2025

SELL
$57.89 - $64.73 $40,754 - $45,569
-704 Reduced 2.84%
24,117 $1.09 Billion
Q3 2023

Sep 05, 2025

SELL
$57.89 - $64.73 $453,510 - $507,094
-7,834 Reduced 35.91%
13,983 $812 Million
Q2 2023

Sep 05, 2025

SELL
$63.71 - $70.74 $2.28 Million - $2.53 Million
-35,802 Reduced 62.14%
21,817 $1.4 Billion
Q1 2023

Sep 05, 2025

BUY
$65.71 - $74.53 $2.16 Million - $2.44 Million
32,798 Added 132.14%
57,619 $3.99 Billion

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $99.2B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Abn Amro Investment Solutions Portfolio

Follow Abn Amro Investment Solutions and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Abn Amro Investment Solutions, based on Form 13F filings with the SEC.

News

Stay updated on Abn Amro Investment Solutions with notifications on news.